Aurobindo Pharma Gains 3% After USFDA Approval for Dasatinib Tablets,
Aurobindo Pharma’s shares rose nearly 3% after its subsidiary, Eugia Pharma, received USFDA approval to market Dasatinib Tablets for leukaemia treatment.
Source
<meta name="google-adsense-account" content="ca-pub-6363428395369086">
- 3 Smart Ways To Invest In Gold For Better Returns
- BluSmart’s exit, new business models, and legal hurdles – What’s